|
T11557 |
FASN-IN-3
|
|
Fatty Acid Synthase
|
|
FASN-IN-3 is an inhibitor of fatty acid synthase (FASN). |
|
T11267 |
FASN-IN-1
|
TVB-2460 |
Fatty Acid Synthase
|
|
FASN-in-1 is an effective, specific inhibitor of fatty acid synthase (FASN), a compound specifically designed to target and inhibit the activity of the enzyme involved in fatty acid synthesis, potentially disrupting fatt... |
|
T15271 |
Denifanstat
|
FASN-IN-2,TVB2640,TVB-2640 |
Fatty Acid Synthase
|
|
Denifanstat (FASN-IN-2) is a Fatty Acid Synthase (FASN) inhibitor(IC50 of 0.052 μM and an EC50 of 0.072 μM),with potential antineoplastic activity. |
|
T37776 |
FASN-IN-4 tosylate
|
|
|
|
FASN-IN-4 tosylate is a potent fatty acid synthase (FASN) inhibitor, exhibiting an IC50 value of 10 nM. Additionally, it demonstrates inhibitory activity against SARS-CoV-2, with an EC50 of 18.6 nM [2]. |
|
T11266 |
FASN-IN-4
|
FAS-IN-1 |
Others
|
|
FAS-IN-1 is a potent inhibitor of Fatty acid synthase (FAS) wtih IC50 of 10 nM. |
|
T79416 |
FASN-IN-6
|
|
|
|
FASN-IN-6 (compound 44), a potent fatty acid biosynthesis (FAB) inhibitor, serves as an antibacterial agent, exhibiting minimum inhibitory concentrations (MICs) of 1 μg/mL for S. aureus ATCC 25923 and 4 μg/mL for E. faec... |
|
T62925 |
FASN-IN-5
|
|
|
|
FASN-IN-5 (example 11) is a FASN inhibitor that can be used in studies of TH17 or CSF1-mediated diseases or disorders (e.g. cancer, immune disorders, obesity). |
|
T7947 |
FT113
|
|
Fatty Acid Synthase
|
|
FT113 is a novel potent inhibitor of fatty acid synthase (fasn, IC50 : 213 nM),and exhibits anti-cancer activity |
|
T0686 |
Orlistat
|
Ro-18-0647,Tetrahydrolipstatin |
Apoptosis
,
Others
,
Fatty Acid Synthase
|
|
Orlistat (Tetrahydrolipstatin) is an Intestinal Lipase Inhibitor. The mechanism of action of orlistat is as a Lipase Inhibitor. |
|
T17180 |
TVB-3166
|
|
Apoptosis
,
Others
,
Fatty Acid Synthase
|
|
TVB-3166 induces apoptosis and inhibits in-vivo xenograft tumor growth. TVB-3166 is a reversible and selective fatty acid synthase inhibitor (IC50s: 42 nM and 81 nM for biochemical FASN and cellular palmitate synthesis,... |
|
T17181 |
TVB-3664
|
|
Fatty Acid Synthase
|
|
TVB-3664 significantly decreases tubulin palmitoylation and mRNA expression. TVB-3664 is a reversible and highly bioavailable fatty acid synthase inhibitor (IC50: 18 nM and 12 nM for human and mouse cell palmitate synthe... |
|
T7798 |
FGH10019
|
FGH-10019 |
NPC1L1
,
Fatty Acid Synthase
|
|
FGH10019 is a novel inhibitor of sterol regulatory element-binding protein (SREBP) ( IC50 :1 μM). |
|
T9266 |
Fatostatin
|
|
Lipid
,
Fatty Acid Synthase
|
|
Fatostatin is a specific inhibitor of SREBP activation, it impairs the activation of SREBP-1 and SREBP-2. Fatostatin binds to SCAP (SREBP cleavage-activating protein), and inhibits the ER-Golgi translocation of SREBPs. |
|
T12437 |
PF429242 dihydrochloride
|
|
S1P Receptor
|
|
PF429242 dihydrochloride is a reversible and competitive inhibitor of S1P (IC50 of 175 nM). |
|
T36841 |
IPI-9119
|
|
Fatty Acid Synthase
|
|
IPI-9119 is an orally active, selective and irreversible FASN inhibitor (IC50 = 0.3 nM). |
|
T10656 |
Trans-C75
|
(±)-C75 |
Others
,
Fatty Acid Synthase
|
|
trans-C75 ((±)-C75) is an enantiomer of C75. C75 is an inhibitor of fatty-acid synthase (FASN). |
|
T6832 |
Fatostatin hydrobromide
|
Fatostatin HBr,Fatostatin A,Fatostatin A HBr,Fatostatin |
NPC1L1
,
Fatty Acid Synthase
|
|
Fatostatin hydrobromide (Fatostatin A HBr) ia an inhibitor of sterol regulatory element binding protein (SREBP). It impairs the activation of SREBP-1 and SREBP-2. |
|
T27307L |
Fasnall HCl
|
Fasnall HCl（929978-58-5 Free base） |
Fatty Acid Synthase
|
|
Fasnall HCl is a selective FASN inhibitor that acts through its co-factor binding sites. Fasnall HCl also shows potent anti-tumor activity in the MMTV-Neu model of HER2(+) breast cancer, particularly when combined with c... |
|
T27307 |
Fasnall
|
|
Fatty Acid Synthase
|
|
Fasnall is a selective FASN inhibitor that acts through its co-factor binding sites. Fasnall shows potent anti-tumor activity in the MMTV-Neu model of HER2(+) breast cancer, particularly when combined with carboplatin. |
|
T10657 |
C75
|
C-75 |
Fatty Acid Synthase
|
|
C75 is an inhibitor synthetic fatty-acid synthase (FASN) and inhibits prostate cancer cells PC3 (IC50: 35 μM). |
|
T15429 |
GSK2194069
|
|
Others
,
NADPH
,
Fatty Acid Synthase
|
|
GSK2194069 is an active β-keto reductase (KR)-specific inhibitor of fatty acid synthase (FASN) with an IC50 of 7.7 nM in an assay for the detection of released CoA.GSK2194069 inhibits the proliferation of FAS in cancer c... |
|
T21831 |
UCM05
|
G28UCM |
Fatty Acid Synthase
|
|
UCM05 (G28UCM) is a potent inhibitor of fatty acid synthase (FASN) with efficacy against HER2+ breast cancer xenografts, including in cell lines resistant to anti-HER2 drugs [1]. Additionally, it functions as an inhibito... |
|
T70978 |
5-Hydroxy Lansoprazole Sulfide
|
|
|
|
5-Hydroxy Lansoprazole Sulfide is an inhibitor of fatty acid synthase (FASN). FASN, which is responsible for de-novo synthesis of lipids, has been found to be overexpressed in cancerous tissue. 5-Hydroxy Lansoprazole Sul... |
|
T11574 |
HS79
|
|
Others
|
|
|
|
T11575 |
HS80
|
|
Others
|
|
|
|
T78873 |
CTL-12
|
|
|
|
CTL-12, a fatty acid synthase (FASN) inhibitor (IC50: 2.5 μM), induces apoptosis and disrupts the cell cycle at the Sub-G1/S phase. It upregulates caspase-9 and the apoptosis marker Bax, while downregulating the anti-apo... |
|
T78872 |
CTL-06
|
|
|
|
CTL-06, a Fatty Acid Synthase (FASN) inhibitor with an IC50 of 3 μM, induces apoptosis, while CTL-12 impedes cell cycle progression in the Sub-G1/S phase and modulates apoptotic and anti-apoptotic markers by upregulating... |
|
T69671 |
SR1903 TFA
|
|
|
|
SR-1903 is a modulator of retinoic acid receptor-related orphan receptor γ (RORγ) and liver X receptor (LXR). It is an inverse agonist of RORγ and an agonist of LXR. It also binds to peroxisome proliferator-activated rec... |
|
T70882 |
Orlistat-d3
|
|
|
|
Orlistat-d3 is intended for use as an internal standard for the quantification of orlistat by GC- or LC-MS. Orlistat is a digestive lipase inhibitor. It inhibits diacylglycerol lipase α (DAGLα), DAGLβ, α/β-hydrolase doma... |
|
T35638 |
SR 1903
|
|
|
|
SR 1903 is a modulator of retinoic acid receptor-related orphan receptor γ (RORγ) and liver X receptor (LXR).1 It is an inverse agonist of RORγ (IC50 = ~100 nM in a cell-based reporter assay) and an agonist of LXR. It al... |
